Robert Schoen, MD
Rheumatology · Guilford, CTNPI 1689652208
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $491,773 of the $637,870 with a category attached, or 77.1%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.7%. Among rheumatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,322 payments — averaging $482.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$132K
- AbbVie$113K
- Lilly USA, LLC$91K
- Janssen Scientific Affairs, LLC$78K
- Johnson & Johnson$76K
- Sanofi$37K
- plus $111K from 25 others
Across 2 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$9K
What the payments were for
- Consulting fees$43,8267%
- Speaking & faculty fees$491,77377%
- Travel & lodging$75,67012%
- Food & beverage$26,1074%
- Education$4940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 219 | $132,098 |
| AbbVie | 276 | $112,770 |
| Lilly USA, LLC | 145 | $90,992 |
| Janssen Scientific Affairs, LLC | 68 | $77,829 |
| Johnson & Johnson | 101 | $76,032 |
| Sanofi | 35 | $37,366 |
| UCB, Inc. | 129 | $37,007 |
| Regeneron Healthcare Solutions, Inc. | 42 | $20,667 |
| E.r. Squibb & Sons, L.L.C. | 49 | $14,717 |
| Pfizer | 63 | $14,495 |
| Genentech USA, Inc. | 36 | $10,797 |
| Bristol Myers Squibb | 32 | $10,436 |
| AstraZeneca(2 entities) | 35 | $753 |
| GSK | 17 | $331 |
| Novartis | 18 | $285 |
| Boehringer Ingelheim | 10 | $241 |
| Mallinckrodt Hospital Products Inc. | 6 | $190 |
| Fresenius Kabi USA, LLC | 4 | $106 |
| Sobi, Inc | 5 | $97 |
| Merck | 7 | $97 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $95 |
| Mallinckrodt Enterprises LLC | 4 | $72 |
| Sandoz | 2 | $66 |
| Medexus Pharma, Inc. | 4 | $64 |
| Radius Health, Inc. | 2 | $61 |
| Scilex Pharmaceuticals Inc. | 3 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $58 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Organon | 1 | $19 |
| Biocon Biologics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$637,870 in reported general payments places this provider in the 95th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 47 | $353,705 |
| Humira(Cf) PenAdalimumab | 40 | $288,810 |
| Orencia ClickjectAbatacept | 43 | $248,154 |
| Xeljanz XrTofacitinib Citrate | 32 | $193,370 |
| OrenciaAbatacept/Maltose | 35 | $165,573 |
| KevzaraSarilumab | 36 | $156,351 |
| HumiraAdalimumab | 11 | $142,991 |
| RinvoqUpadacitinib | 18 | $127,723 |
| EnbrelEtanercept | 13 | $112,970 |
| BenlystaBelimumab | 40 | $107,317 |
| OtezlaApremilast | 21 | $95,538 |
| Cimzia (2 Pack)Certolizumab Pegol | 16 | $88,422 |
| XeljanzTofacitinib Citrate | 12 | $68,294 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 24 | $58,382 |
| Hydroxychloroquine Sulfate | 218 | $9,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira, Rinvoq | $112,770 | $270,71429 claims |
| AmgenEnbrel, Otezla, Evenity (2 Syringes) | $132,098 | $266,89058 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $14,717 | $165,57335 claims |
| SanofiKevzara | $37,366 | $156,35136 claims |
| GSKBenlysta | $331 | $107,31740 claims |
| UCB, Inc.Cimzia (2 Pack) | $37,007 | $88,42216 claims |
| PfizerXeljanz | $14,495 | $68,29412 claims |
| Medexus Pharma, Inc.Rasuvo | $64 | $8,17015 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $61 | $2,46113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 118 rheumatology providers in Connecticut.
Other rheumatology in Guilford
- Kenneth MillerDanbury$873K
- Bret SohnStamford$447K
- Fotios KoumpourasNorth Haven$314K
- James SeiboldFarmington$300K
- Michael SpiegelDanbury$215K
- John MagaldiTorrington$157K
- Archana SharmaBristol$98K
- Richard RoseffDanbury$84K
- Beth ValashinasOrange$81K
- Germano GuadagnoliTrumbull$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.